chief executive anders fink vadsholtcfo head bo jesper hansenchairman topotarget nasdaq copenhagen topo copenhagenbased biotechnology company focused discovery development drugs therapies treat cancer merged bioalliance pharma part onxeo founded group topotarget involved collaborations academia industry began collaborating national cancer institute component us national institutes health since acquisition prolifix collaborating netherlands cancer institute also collaborate rigshospitalet national hospital denmark topotarget also collaborated companies including novartis since lundbeck october topotarget member danish innovation network biopeople since topotargets revenue company publicly traded omx nordic exchange copenhagen symbol topo member medicon valley alliance ceo peter buhl jensen md end topotarget total employees worked drug development including assay development medicinal chemistry preclinical research clinical trials marketing sales employees medical research fields topotarget public partners many areas world notably rigshospitalet copenhagen frankfurt university hospital oxford university hospital national cancer institute us topotarget founded clinicians specializing molecular mechanisms cancer since start grown mostly acquisitions topotarget acquired prolifix ltd based united followed purchase cancer drugs ag germany topotarget employees specializing areas drug discovery development acquired apoxis two products topotarget currently employs people denmark germany switzerland uk currently topotarget nine drugs clinical development well extensive portfolio small molecule drug candidates preclinical phase savenetotect topotargets first marketed product released october europe october united states causing large jump revenue million dkk million dkk patients treated via drugs topotargets since inception topotarget developed strong twopronged strategy expanding drug topotarget splits focus inlicensing outlicensing opportunities maximize utilization available skills resources inlicensing takes advantage internal talent focuses preclinical early clinical development small molecule drugs phase trials outlicensing products larger pharmaceutical companies however facilitates progression drugs broad market potential final stages clinical development regulatory approval marketing taking advantage established reputations knacks navigating later stages commercialization summarize strategy topotarget states company track record successfully managing alliances major pharmaceutical companies biotechnology companies academic institutions company continue strategy order develop portfolio oncology product candidates projects balanced shorterterm niche products longerterm products broad potential allowing sector focus specialty drug development timeline maximizes topotargets use time resources increase productivity number inlicensing collaborations expanded topotargets drug pipeline june topotarget entered licensing collaboration agreement curagen corporation respect research development commercialization group small molecules inhibit histone deacetylase hdac one proved particularly promising forms basis topotargets research collaboration national cancer institute october astellas sold exclusive worldwide license group compounds potential anticancer immunosuppressive activity currently undergoing preclinical evaluation leo pharma sold topotarget license preclinical hdac inhibitor also undergoing evaluation treatment cancer inflammatory conditions april sales rights compound transferred topotarget october h lundbeck sold development rights sigma receptor ligand siramesine licensing potential cancer therapeutics external sources developing drug candidates within topotarget hopes establish broad array drugs target underlying molecular mechanisms cancer viability compound established internally topotarget relays remaining responsibilities development process commercial collaborators outlicensing agreements three prominent bodies maintain outlicensing contracts national cancer institute usa netherlands cancer institute righospitalet copenhagen topotarget working division cancer treatment diagnosis nci since develop new anticancer agents currently nci handling clinical development topotargets hdac inhibitor belinostat ncis efforts focused determining molecular basis belinostats anticancer activity drugs viability combination drug therapy netherlands cancer institute provides topotarget access extensive research conducted division carcinogenesis uses advanced techniques functional genomics identify novel genes roles carcinogenesis may saw establishment fiveyear research collaboration agreement topotarget copenhagens rigshospitalet test drug topotect effectiveness brain metastases relationships allow topotarget advance products clinical development immediate resources insufficient task topotargets portfolio included belinostat savicol baceca avugane topotecta zemab inhibitors savene aka totect topotargets single marketed drug end p generic name savene savene developed topotarget authorized put market july european commission treatment anthracycline extravasation savene developed topotarget used treatment anthracycline extravasation rare complication chemotherapy anthracycline extravasation defined unintentional installation leakage perivascular subcutaneous spaces administration savene works inhibiting dna topoisomerase ii target anthracycline chemotherapy drug binds dna topoisomerase ii different step catalytic cycle anthracyclines locks enzyme conformational form longer affected anthracyclines drug delivered readytouse kit containing savene powder savene pp belinostat p topotargets lead product currently latestage clinical development treatment hematological malignancies solid tumors belinostat histone deacetylase inhibitor hdaci topotarget expects launch initial regulatory study using belinostat monotherapy treat peripheral tcell lymphoma ptcl beginning october preliminary results released phase ii clinical trial intravenous belinostat combination carboplatin paclitaxel relapsed ovarian final results late phase ii trial cell lymphoma belinostat granted orphan drug fast track designation september belinostat phase ii pivotal trial nda submission planned savicol formerly known peac pulse enhanced acetylation anticancer drug candidate treats familial adenomatous polyposis fap savicol delivers valproic acid proprietary builds specific pharmacokinetic release pattern projected inhibit certain hdac enzymes efficient manner savicol entered phase ii studies topotarget treatment colorectal polyps fap patients orphan drug status granted savicol united states baceca comprises topical formulation valproic acid vpa treatment hyperproliferative skin diseases including basal cell carcinoma precancerous actinic keratosis vpa primarily targets hdac class enzymes involved cell proliferation tumorigenesis baceca currently phase ii clinical avugane novel proprietary formulation hdaci vpa potential used topical treatment inflammatory skin diseases including common acne randomized phase ii clinical studies performed avugane april studies conducted since investigate clinical utility drug results successful topotarget may consider conduction trials diseases including psoriasis atopic topotecta topoisomerase ii inhibitor treatment brain metastases drug based compound savene dexrazoxane currently involved phase clinical trials treatment brain metastases common secondary condition patients lung cancer breast zemab comprises antibodytoxin treatment specific types cancers form protein pg recombinant protein product targets receptor overexpressed breast cancer often marker aggressive disease receptor also believed involved certain cancers including head neck cancers next clinical studies zemab expected initiated start october clinical trials also known megafasligand recombinant fusion protein protein derived proapoptotic human fas ligand fasl protein causes cell death cancerous cells mechanism targeting fas receptors surface cancer cells inducing cell apoptosis phase study currently conducted patients untreatable advanced refractory solid drug inhibits growth human tumors potent specific inhibitor key enzyme involved synthesis nad called nmprt worldwide development marketing rights acquired astellas october drug provides new therapeutic approach cancer topotarget opened three separate clinical studies ctl trial terminated interim review point due lack therapeutic recombinant protein developed ectodysplasin gene product used treat rare human genetic disease linked mutations gene disease reduces patients ability sweat increases hypersensitivity heat aberrant dentition hairlessness dry skin completed preclinical development shown potential animal models xlinked hypohidrotic ectodermal dysplasia xlhed gained orphan drug status fda february topotarget plans sell project another company outlicense number heat shock protein small molecule inhibitors developed topotarget several compounds showing high potency several cancer cell lines particularly cell lines overexpress receptors project still preclinical trials topotarget process outlicensing product looking companies collaborate topotarget several drugs preclinical development current target heat shock protein key protein folding maturation topotarget currently looking small molecule drugs inhibit function induce apoptosis current molecules shown great promise undergoing optimization evaluation order obtain patent topotarget also studying mechanism action behind mtor mammalian target rapamycin pathway understand targets antitumor drugs currently looking find lead compound order continue studies topotarget also looking drugs interrupt hdac activity cancer therapy diseases like malaria cns disorders httpsenwikipediaorgwikitopotarget